the measurement of anti-streptokinase antibodies can distinguish the patients who may benefit from streptokinase and those who should be treated with some other thrombolytic regimen. neutralising titration test is a commonly used classical assay for measuring anti-streptokinase antibodies and in this assay the ability of anti-streptokinase antibodies in patients' sera in preventing the lytic ef...

tenecteplase is a variant of tissue plasminogen activator (t-pa) which has better pharmacokinetic properties and more selective thrombolytic activity. in the present study, we describe a rapid method to introduce three sets of mutation into defined positions in t-pa cdna by a site-directed mutagenesis based on a megaprimer pcr approach to produce tenecteplase coding sequence where amino acids a...

standard protocols should be established for treating eligible stroke patients with tissue plasminogen activator (tpa) (recommendation class i, level of evidence b). the iranian standard protocol of intravenous thrombolysis with recombinant tissue plasminogen activator (ivttpa) is the best possible and easy to use method for performing intravenous thrombolysis in iran. this protocol overcomes p...

objective: to evaluate the efficacy and safety of intravenous and catheter directed thrombolysis by recombinant tissue plasminogen activator (alteplase) in the patients with non-traumatic acute limb ischemia (ali). methods: this was a randomized clinical trial being performed between 2009 and 2011 in mashhad university of medical sciences. we included those patients who were<75 years, with symp...

background: in patients with acute ischemic cerebral infarction, thrombolytic therapy using intravenous tissue plasminogen activator (iv?tpa) necessitates precise documentation of symptoms’ onset. the aim of this study was to identify major barriers related to the iv?tpa injection in such patients. materials and methods: between 2014 and 2015, patients with definitive diagnosis of acute cerebra...

purpose: to compare the effect of tissue plasminogen activator (tpa) and aspirin in patients with central retinal vein occlusion. methods: a prospective interventional study was conducted on patients with central retinal vein occlusion of less than 28 days&apos; duration. patients in the tpa group received 100 μg intravitreal tissue plasminogen activator and the patients who declined intravitre...

stroke is an important cause of disability and death worldwide, with the majority of strokes occurring in older people. thrombolysis with recombinant tissue plasminogen activator (r-tpa) is the approved treatment for acute ischemic stroke. a major concern of physicians, who treat acute ischemic stroke with recombinant tissue plasminogen activator (r-tpa,) is the risk of intracerebral hemorrhage...

no abstract

background: escherichia coli (e. coli) is the most extensively used host for the production of recombinant proteins. however, most of the eukaryotic proteins are typically obtained as insoluble, misfolded inclusion bodies that need solubilization and refolding. reteplase as a highly disulfide-bonded recombinant protein is an example of difficult to express protein in e. coli. methods: in this s...